Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Cimas-Hernando

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Advances in Therapy|September 15, 2021
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTORCarmen M Labandeira, Maria G Alonso Losada, Rosa Yáñez Baña, et al.
Neurologia|October 29, 2021
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameterA Pato Pato, E Costa Arpín, A Rodríguez Regal, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 23, 2021
Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR studyDiego Santos García, Iria Cabo López, Carmen Labandeira Guerra, et al.
Revista De Neurologia|July 11, 1998
[Gamma-sarcoglycanopathy: clinico-pathological and genetic study of 11 cases]D García-García, S Teijeira-Bautista, J M Fernández-Rodríguez, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Advances in Therapy|September 15, 2021
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTORCarmen M Labandeira, Maria G Alonso Losada, Rosa Yáñez Baña, et al.
Neurologia|October 29, 2021
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameterA Pato Pato, E Costa Arpín, A Rodríguez Regal, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 23, 2021
Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR studyDiego Santos García, Iria Cabo López, Carmen Labandeira Guerra, et al.
Revista De Neurologia|July 11, 1998
[Gamma-sarcoglycanopathy: clinico-pathological and genetic study of 11 cases]D García-García, S Teijeira-Bautista, J M Fernández-Rodríguez, et al.
Pageof 2